Premium
CHEMO‐FREE TRIPLET COMBINATION OF TGR‐1202, UBLITUXIMAB, AND IBRUTINIB IS WELL TOLERATED AND HIGHLY ACTIVE IN PATIENTS WITH ADVANCED CLL AND NHL.
Author(s) -
Nastoupil L.,
Lunning M.A.,
Vose J.M.,
Schreeder M.T.,
Siddiqi T.,
Flowers C.R.,
Cohen J.B.,
Burger J.A.,
Wierda W.G.,
O'Brien S.,
Sportelli P.,
Miskin H.P.,
Purdom M.A.,
Weiss M.S.,
Fowler N.H.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_101
Subject(s) - ibrutinib , medicine , rash , neutropenia , mantle cell lymphoma , tolerability , gastroenterology , rituximab , adverse effect , oncology , lymphoma , chronic lymphocytic leukemia , leukemia , chemotherapy